| 0.255 -0.004 (-1.51%) | 10-04 11:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.31 |
1-year : | 0.36 |
| Resists | First : | 0.27 |
Second : | 0.31 |
| Pivot price | 0.22 |
|||
| Supports | First : | 0.2 |
Second : | 0.17 |
| MAs | MA(5) : | 0.24 |
MA(20) : | 0.22 |
| MA(100) : | 0.24  |
MA(250) : | 0.37 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 92.4 |
D(3) : | 84 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 1.2 | Low : | 0.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CPHI ] has closed below upper band by 14.6%. Bollinger Bands are 16.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.26 - 0.26 | 0.26 - 0.26 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.26 - 0.26 | 0.26 - 0.26 |
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
Thu, 03 Oct 2024
CPHI’s 52-Week Rollercoaster: From $0.17 to $1.21 – What’s Next for Investors? - The InvestChronicle
Thu, 03 Oct 2024
Analytical Overview: China Pharma Holdings Inc. (CPHI)’s Ratios Tell a Financial Story - The Dwinnex
Tue, 01 Oct 2024
Check out these key findings about China Pharma Holdings Inc. (CPHI) - SETE News
Fri, 27 Oct 2023
CPHI Annual Report Predicts VC Capital (Re)entry and Contract Services Growth in 2024 - European Pharmaceutical Manufacturer
Wed, 23 Aug 2023
Is China Pharma Holding (CPHI) A Hidden Gem or A Value Trap? - Yahoo Finance
Fri, 02 Dec 2022
China Pharma Announces Receipt of Noncompliance Notice from NYSE American - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 17 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 57.5 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 94 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | -70.5 % |
| Operating Margin | -150.5 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | -15.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0.7 |
| Price to Cash Flow | 13.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|